Biodistribution, pharmacokinetics, and dosimetry of 177Lu-,90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: The mass effect

Journal of Nuclear Medicine

Volumn 58, Issue 9, 2017, Pages 1435-1441

  Nicolas, Guillaume P ^a   Mansi, Rosalba ^a   McDougall, Lisa ^a   Kaufmann, Jens ^b   Bouterfa, Hakim ^b   Wild, Damian ^a   Fani, Melpomeni ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b IPSEN   (France)

Author keywords

177Lu; Neuroendocrine tumors; Radionuclide therapy; Receptor targeting; Somatostatin receptor antagonists

Indexed keywords

ANTINEOPLASTIC AGENT; GELATIN; INDIUM OPS201 IN 111; LUTETIUM OPS201 LU 177; OPS201; OXODOTREOTIDE LU 177; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; YTTRIUM OPS201 Y 90; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 177LU-DOTA-JR11; COORDINATION COMPOUND; CYCLOPEPTIDE; INDIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOEQUIVALENCE; BONE MARROW; CONTROLLED STUDY; DOSE RATIO; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; ISOTOPE LABELING; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHARMACOKINETIC ASSAY; PRIORITY JOURNAL; RADIATION DOSE; THERAPEUTIC INDEX; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; HEK293 CELL LINE; HUMAN; RADIOMETRY; TISSUE DISTRIBUTION;

ANIMALS; COORDINATION COMPLEXES; FEMALE; HEK293 CELLS; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; RADIOMETRY; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 85015674235     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.191684     Document Type: Article

References (30)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26: 3063-3072.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9: 61-72.
3. Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15: E8-e21.
4. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5: 382-393.
5. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2): 42S-55S.
6. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]- TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29: 2416-2423.
7. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26: 2124-2130.
8. Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46: 225-238.
9. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103: 16436-16441.
10. Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52: 1886-1890.
11. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52: 1412-1417.
12. Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem. 2008;51: 4030-4037.
13. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study. J Nucl Med. 2014;55: 1248-1252.
14. Reubi JC, Waser B, Macke H, Rivier J. Highly increased 125I-JR11 antagonist binding in vitro reveals novel indications for sst2 targeting in human cancers. J Nucl Med. 2017;58: 300-306.
15. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5: 730-739.
16. Fani M, Del Pozzo L, Abiraj K, et al. PET of somatostatin receptor-positive tumors using 64Cu- And 68Ga-somatostatin antagonists: The chelate makes the difference. J Nucl Med. 2011;52: 1110-1118.
17. Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53: 1481-1489.
18. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med. 1993;34: 689-694.
19. Wolfsegger MJ, Jaki T. Estimation of AUC from 0 to Infinity in serial sacrifice designs. J Pharmacokinet Pharmacodyn. 2005;32: 757-766.
20. Dalm SU, Nonnekens J, Doeswijk GN, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57: 260-265.
21. Sabet A, Ezziddin K, Pape UF, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41: 505-510.
22. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376: 125-135.
23. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35: 152-156.
24. Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36: 623-627.
25. de Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26: 693-698.
26. Bernhardt P, Kolby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Biodistribution of 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: Influence of amount injected and route of administration. Nucl Med Biol. 2003;30: 253-260.
27. Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol. 2010;37: 265-275.
28. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTANOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37: 2004-2010.
29. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40: 800-816.
30. Tulipano G, Soldi D, Bagnasco M, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454: Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology. 2002;143: 1218-1224.